Clinical Trial: Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational
Official Title: Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.
Brief Summary: Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. This can result in endstage renal failure. Complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. Our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. This could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.
Detailed Summary:
Sponsor: University Hospital, Ghent
Current Primary Outcome:
- C3a-des-Arg measuring (as a marker of activation). [ Time Frame: at time 0, at 15 minutes, at 60 minutes and at 180 minutes ]
- white blood cell count [ Time Frame: before and after 15 minutes of hemodialysis ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University Hospital, Ghent
Dates:
Date Received: June 29, 2009
Date Started: August 2009
Date Completion: July 2015
Last Updated: December 4, 2014
Last Verified: December 2014
